Breast Cancer Treatment Advances: 5 Research Breakthroughs to Know 

Written by: Dana-Farber Staff
Medically Reviewed By: Sara M. Tolaney, MD, MPH

Breast cancer research is driving the development of new therapies for breast cancer. Through clinical trials and work in research labs, including those at Dana-Farber Cancer Institute, new treatments are tested — and if successful, made available to patients who need them.

Test Tubes And Pipette - Research In Laboratory Test Tubes

Breast cancer is now understood as a group of distinct diseases. Any patient’s cancer is distinct, not only in the molecular makeup of the tumor cells, but also the patient’s response to prior therapy and the state of their immune system.

As a result, “the future of breast cancer therapy is tied to the idea of individualizing treatment for each patient, and research being done today is increasingly making that possible,” says Sara Tolaney, MD, MPH, chief of the Breast Oncology Center at Dana-Farber.

Some of the hot areas of treatment advances and research in breast cancer include:

Antibody-drug conjugates (ADCs) in breast cancer treatment

Dana-Farber researchers have been leading clinical trials of novel medicines for breast cancer called antibody-drug conjugates, or ADCs, which are drugs made up of an antibody linked to a chemotherapy drug.

These medicines use an antibody to target receptors on the surface of cancer cells and deliver the chemotherapy drug into the tumor. This means that patients can receive more potent therapy than standard chemotherapy, potentially with fewer side effects.

ADCs for Metastatic Breast Cancer

Currently, every major form of metastatic breast cancer has at least one ADC approved by the U.S. Food and Drug Administration (FDA). In more recent research, the earliest approved ADC, T-DM1, has been superseded by the next-generation ADC, T-DXd, for metastatic HER2-positive breast cancer.

In addition, ADCs are moving into earlier lines of treatment for metastatic breast cancer. For example, Tolaney led a clinical trial that backed the approval of T-DXd plus pertuzumab, a HER2-targeting monoclonal antibody, as the first treatment patients receive for advanced HER2-positive breast cancer. Other trials led by Tolaney support the potential for additional ADCs to become the first treatments patients receive for advanced triple-negative breast cancer and the first chemotherapy for advanced hormone-receptor (HR)-positive breast cancer.

“This could be the year that the first chemotherapy you get in any form of metastatic breast cancer could actually be an ADC,” says Tolaney.

With this advancement, more patients will be able to receive this advanced therapy first, before their cancer has developed ways to resist therapies.

Research into ADCs in metastatic breast cancer continues as Dana-Farber investigators explore the use of ADCs in combination with other therapies, such as immunotherapies, to improve efficacy for patients with metastatic breast cancer.

ADCs and brain metastases

When ADCs were first introduced, conventional wisdom was that the compounds were too large to cross the blood-brain barrier. Research in the lab of Jean Zhao, PhD, at Dana-Farber, showed in animal models that T-DXd could enter the brain and shrink tumors that can occur there when breast cancer spreads.

Based on this evidence, Nancy Lin, MD, director of Dana-Farber’s Program for Patients with Breast Cancer Brain Metastases, led a trial showing that T-DXd benefited patients with metastatic HER2-positive breast cancer with brain metastases. The drug showed substantial anti-cancer activity in brain metastases in patients with HER2-positive breast cancer, bringing hope to patients who have or are at risk of developing brain metastases.

Building on this discovery, Lin is leading several trials exploring the potential for other ADCs to benefit patients with brain metastases.

ADCs for early-stage breast cancer

Early-stage breast cancer has not yet spread beyond the breast or lymph nodes. One ADC, T-DM1, is already approved for certain patients with high-risk early-stage HER2-positive breast cancer and recent data has shown that T-DXd can help prevent recurrence in patients with high-risk residual HER2-positive disease.

Trials are underway to determine how ADCs can continue to improve treatment for early-stage disease. These trials are testing ADCs in combination with other treatments, such as immunotherapies. They are also exploring the benefits of treating patients with ADCs before surgery and after surgery.

Immunotherapy advances in breast cancer

Enormous amounts of research are going into immunotherapy, which has become a pillar of treatment for several types of cancer. The immune checkpoint inhibitor pembrolizumab, for example, is approved for the treatment of triple-negative breast cancer.

An up-and-coming area of immunotherapy research is looking into the use of bispecific antibody therapies to treat breast cancer. Bispecific antibodies are designed to recognize flags on two different cell types to bring those cells close together and trigger a stronger anti-cancer response.

Dana-Farber investigators will be offering this innovative approach to eligible patients in a clinical trial. The trial will evaluate a bispecific antibody that targets the immune checkpoint PD-1 (the target of pembrolizumab) and an anti-angiogenic factor called VEGF for patients with metastatic triple-negative breast cancer.

Can metastatic HER2-positive breast cancer be cured?

Treatments for metastatic HER2-positive breast cancer have advanced so dramatically that some patients are experiencing prolonged control of their disease. This observation inspired Dana-Farber researchers to ask if some of these patients might be cured and might no longer need to be treated indefinitely with medicines to reduce the risk of recurrence.

To answer the question, they launched a trial called STOPHER2, led by Lin, that invites patients who are experiencing these exceptional responses to choose to stop treatment or continue. The study aims to determine if stopping treatment is safe, and if liquid biopsies can be used to monitor patients for early signs of recurrence.

Simultaneously, the Dana-Farber team is also investigating whether some of the most effective available treatment options might be combined into an intensified treatment regimen that increases the number of patients who experience exceptional responses.

“As our treatments continue to improve, it does make us wonder if we could potentially cure metastatic HER2-positive breast cancer,” says Tolaney.

New Hormone therapies for breast cancer

Tumors that express the estrogen receptor, a hormone receptor, account for roughly 70% of all breast cancer cases. Metastatic forms of these hormone receptor (HR)-positive cancers can be difficult to treat. Currently, patients receive a combination of hormone therapy plus a targeted therapy called a CDK 4/6 inhibitor as a first line of treatment.

Dana-Farber investigators are leading a trial of a new form of hormone therapy, called giredestrant, plus everolimus, an mTOR inhibitor, to determine if it could benefit patients who have already received a CDK 4/6 inhibitor. Giredestrant is a next-generation selective estrogen receptor degrader (SERD) that works by binding to the estrogen receptor and promoting its degradation, preventing estrogen from stimulating cancer growth.

Results of a phase III trial led by Dana-Farber’s Erica Mayer, MD, MPH, showed significantly improved progression-free survival for patients taking this novel combination compared to standard of care and could support FDA approval of the regimen.

Preventing recurrence in early-stage breast cancer

Patients with early-stage breast cancer often receive medicine after their primary treatment is complete, called adjuvant therapy, to reduce the risk of the cancer from coming back. Dana-Farber investigators have led trials exploring novel approaches to reducing the risk of recurrence.

For instance, Dana-Farber investigators have found that CDK4/6 inhibitors reduce the risk of recurrence in patients with HR-positive, HER2-negative high-risk early breast cancer.

Other investigators have found that the oral SERD giredestrant also could reduce the risk of recurrence for patients with high-risk HR-positive breast cancer. This evidence could lead to a change in practice.

“There hasn’t been a new endocrine therapy approved in 20 years, so if approved, that would be a landmark change for the treatment of our patients,” says Tolaney.

About the Medical Reviewer

Sara M. Tolaney, MD, MPH

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy. 

1 thought on “Breast Cancer Treatment Advances: 5 Research Breakthroughs to Know ”

Comments are closed.